Prediction of Incidence of Liver Cancer by Use of Real-time Tissue Elastography
NCT ID: NCT01360892
Last Updated: 2011-05-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
1000 participants
OBSERVATIONAL
2010-09-30
2013-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Assessment of Liver FIBROsis by Real-time Tissue ELASTography in Chronic Liver Disease
NCT01360879
Two-dimensional Shear Wave Elastography for Assessment of Cirrhosis and Portal Hypertension
NCT06358092
Liver and Spleen Stiffness Measured by TE and 2D-SWE for Diagnosis of GOV in Patients With cACLD
NCT06144437
Assessment of Liver Fibrosis and Prognosis in Chinese Patients With CHB Infection Using STE/STQ Elastography
NCT03530657
Liver and Spleen Stiffness Measured by TE and 2D-SWE for Diagnosis of CSPH in Patients With cACLD
NCT06147947
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Every year and for three years, we performed Real-time Tissue Elastography®, blood sampling, gastrointestinal endoscopy. If in the hospital they can perform FibroScan®, FobroScan® also be performed.
Subjects were also performed ultrasonography (US), computed sonography (CT) or magnetic resonance imaging (MRI) evry four or six months.
The time between the Real-time Tissue Elastography®, blood sampling, gastrointestinal endoscopy and FiroScan® must not exceed four weeks.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Chronic hepatitis B or Chronic hepatitis C
Exclusion Criteria
* History of alcohol abuse (alcohol intake \> 20g/day)
* Pregnant or lactating patients
* Psychosis
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kindai University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Department of Gastroenterology and Hepatology, Kinki University Faculty of Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Masatoshi Kudo, Professor
Role: STUDY_CHAIR
Kinki University Faculty of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kinki University Faculty of Medicine
Ōsaka-sayama, Osaka, Japan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
JLOG1003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.